Eli Lilly lands in Washington the week Foundayo and Medicare reshape GLP-1 access

Eli Lilly flew from its Indianapolis headquarters to Ronald Reagan Washington National Airport on the evening of May 19, 2026, a 1h 20m hop aboard its Gulfstream G500 (N307EL). The destination is not a coastal retreat — it is the regulatory and policy epicenter for the company's blockbuster GLP-1 franchise.

The same week, Eli Lilly is navigating the early rollout of Foundayo, its newly approved oral GLP-1 pill for obesity, which executives said has already reached more than 20,000 patients, per an IndyStar report on April 30. The company also is executing a sweeping November 2025 agreement with the Trump administration that caps Medicare Zepbound costs at $50 a month starting this April and extends access to roughly 40 million Americans on government insurance, as detailed in a company news release. Eli Lilly raised its full-year sales guidance by $2 billion after Q1 revenue surged 56% to $19.8 billion, per its April 30 earnings statement.

The flight follows a pattern of Washington-area trips — N307EL went from Indianapolis to Morristown, New Jersey, on May 18 and May 12, and from Indianapolis to Teterboro on May 12 — suggesting policy discussions, FDA meetings, or supply-chain talks are recurring priorities for the pharmaceutical company and its CEO, Dave Ricks.